17.1 C
New York
Tuesday, May 17, 2022

Selecta Biosciences Inc. (SELB) Stock Trends Higher Following Strategic Licensing Agreement with Takeda

Selecta Biosciences Inc. (SELB) stock prices were up by 3.65% as of the market closing on October 1st, 2021. This brought the price per share up to USD$4.33 at the end of the trading day.

SELB Stock Partners with Takeda

October 4th 2021 saw SELB stock announce having entered into a strategic licensing agreement. The biotechnology company will collaborate with Takeda Pharmaceutical Company. The partnership is hoped to facilitate the development of targeted, next generation gene therapies for two indications within the field of lysosomal storage disorders. The strategic collaboration is also designed to leverage the company’s ImmTOR platform, which will enable the redosing of transformative therapies.


Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .

Sponsored


Synergistic Collaboration

Takeda has been targeted as an ideal candidate to help SELB stock maximize the potential of its ImmTOR platform in gene therapy. The partnering company is a global biopharmaceutical leader, whose expertise in rare diseases has instill great confident in the company. Collaboratively, they will circumvent obstacle to existing efforts in AAV-driven gene therapy. The partner companies will also strive to address immunogenicity constraints and unmet patient needs. The collaboration will provide additional validation and help consolidate the robust value of the ImmTOR platform. The company is keen to expand its growing pipeline with its new partner to maintain the momentum generation by its rapidly advancing proprietary gene therapy programs.

Details of Transaction

As per the agreement, SELB stock is entitled to receive an undisclosed upfront payment. In addition, the company will be entitled up to an additional USD$1.124 billion in future additional payments. These additional payments will be spread over the course of the partnership and will be contingent on the achievement of development or commercial milestones.

SELB Stock Builds on Success

SELB stock is keen to expand its network of partnerships as it looks to build a differentiated gene therapy program. These platforms will provide the company with the opportunity to combined novel platform technologies that will aim to solve the challenges presented by first generation therapies. The company’s ImmTOR platform is designed to mitigate unwanted immune responses allowing for redosing. This could have broad applicability across its gene therapy programs for a myriad of diseases.

Future Outlook for SELB Stock

The company reported a strong quarter, consolidated by the strengthening of its network of partners. SELB stock is keen to capitalize on the opportunities afforded to it as a result of its collaboration with Takeda. Current and potential investors are hopeful that management will be able to effectively leverage the combined resources at their disposal. This is hoped to facilitate significant and sustained increases in shareholder value.

Related Videos

Latest news

Related news

Related Videos

LEAVE A REPLY

Please enter your comment!
Please enter your name here